Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05548296 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
A Phase 2 study of Endometrial Adenocarcinoma, sponsored by Acrivon Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 353
- Enrollment target
- 20
- Study locations
NCT05548296: Recruiting Phase 2 study of Endometrial Adenocarcinoma, sponsored by Acrivon Therapeutics.
NCT05548296 is a Phase 2 study of Endometrial Adenocarcinoma that is actively recruiting participants, run by Acrivon Therapeutics. The registered enrollment target is 353 participants, above the 313-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target (13% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05548296, a Phase 2 study of Endometrial Adenocarcinoma, is actively recruiting participants, sponsored by Acrivon Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 353 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
Primary Outcome
Assess Objective Response Rate (ORR) per RECIST v1.1 by computed tomography or magnetic resonance imaging.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG ACR-368
- DIAGNOSTIC_TEST OncoSignature
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- UC San Diego Moores Cancer Center - La Jolla
- USC/Norris Comprehensive Cancer Center - Los Angeles
- Cedars Sinai Medical Center - Los Angeles
- Hoag Cancer Center - Newport Beach
- UC Irvine Health - Orange
- Stanford Cancer Center - Palo Alto
- University of California, Davis Comprehensive Cancer Center - Sacramento
- University of California Los Angeles (UCLA) - Santa Monica
Arizona
- HonorHealth - Phoenix
- Arizona Oncology Associate, PC- HOPE - Tucson
Florida
- Florida Gynecologic Oncology/Regional Cancer Center - Fort Myers
- Mount Sinai Comprehensive Cancer Center - Miami Beach
Georgia
- Emory University - Atlanta
- Northeast Georgia Medical Center - Gainesville
Alabama
- University of South Alabama Mitchell Cancer Institute - Mobile
Alaska
- Alaska Women's Cancer Center - Anchorage
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- University of Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2022-08-29 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 2 |
What NCT05548296 shows while recruiting
NCT05548296 is an interventional study that assigns participants to a tested intervention. The registered 353 participants enrollment target is mid-sized for trials with a published cap, above the 313-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target (13% higher).
The record links to 1 condition, with Endometrial Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Gemcitabine is the first listed.
NCT05548296 names 20 study sites across 9 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT05548296 about?
NCT05548296 is a clinical study titled "A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma". This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
What is the current status of trial NCT05548296?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 353 participants. The study started on 2022-08-29. Estimated completion is 2027-04-30.
What conditions does trial NCT05548296 study?
This clinical trial studies the following conditions: Endometrial Adenocarcinoma.
What interventions are being tested in trial NCT05548296?
The interventions under investigation include: Gemcitabine (DRUG), ACR-368 (DRUG), OncoSignature (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05548296?
This trial is sponsored by Acrivon Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05548296 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05548296's enrollment target sits among peer trials
353 2nd of 13 the highest of 13 other Endometrial Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RECRUITING · Phase 2
-
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
ACTIVE NOT RECRUITING · Phase 2
-
Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
ACTIVE NOT RECRUITING · Phase 2
-
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
COMPLETED · Phase 2
-
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05884775 · 353 participants · NA
Novel Digital Patient-Reported Outcomes Tool for Diabetes Management
- NCT02579967 · 354 participants · Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- NCT02610413 · 354 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
- NCT05729256 · 354 participants · NA
Alcohol and "Heat of the Moment" Sexual Decision Making
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI